U.S. FDA Issues Action Letter for Sugammadex
KENILWORTH, N.J., Aug. 1 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP ) today announced that the U.S. Food and Drug
Administration (FDA) has issued a "not-approvable" letter for sugammadex
sodium injection for the reversal of muscle relaxation during general
anesthesia.
...
European Union's CHMP Issues Positive Opinion on Sugammadex
Anesthesiologists to have new tool that works within minutes, upon European approval
KENILWORTH, N.J., June 2 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP ) today reported that the Committee for Medicinal
Products for Human Use (CHMP) of the Eu...
Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in
Phase III Pivotal Trial Compared to Neostigmine
OSS, the Netherlands, June 11, 2007-Sugammadex - the novel
selective relaxant binding agent (SRBA) being developed by Organon,
the human healthcare business unit of Akzo Nobel - demonstrated in
a Phase III pivotal trial a 9-12 times faster reversal of
neuromuscular blockade as compared to neostigmi...
Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in
Phase III Pivotal Trial as Compared to Neostigmine
OSS, The Netherlands, June 11, 2007 /PRNewswire/ --
Sugammadex -
the novel selective relaxant binding agent (SRBA) being developed
by Organon, the human healthcare business unit of Akzo Nobel -
demonstrated in a Phase III pivotal trial a 9-12 times faster
reversal of neuromuscular blockade as comp...
Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
...s recommended to monitor the recovery of
neuromuscular blockade. The use of
sugammadex in patients with severe renal
impairment is not recommended.
In clinical ...duals, allergic-like reactions (i.e. flushing,
erythematous rash) following
sugammadex were reported.
For full Prescribing Information please go to http://www....
BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
...(moderate block) patients were administered
either
sugammadex or neostigmine plus glycopyrrolate. In the AURORA ... a TOF ratio of 0.9
occurred in 1.4 minutes in the
sugammadex group compared to 17.6 minutes in
the neostigmine/... were
randomized to receive either rocuronium plus
sugammadex or the rapid-onset,
short- duration muscle relaxan...
FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
...decision on approval is
made.
Upon FDA approval,
sugammadex will be the first and only selective
relaxant bind...duced
by rocuronium and vecuronium within minutes.
sugammadex allows for flexible
dosing of muscle relaxation ag...e used. We will continue to work with FDA to bring
sugammadex to
the U.S. market as soon as possible so that ane...
Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
... SAN FRANCISCO, Oct. 16 /PRNewswire/ --
sugammadex -- the novel
selective relaxant binding agent (SRB...e Signal trial compared the efficacy and safety of
sugammadex and
neostigmine/glycopyrrolate for the reversal of...Spectrum trial compared the efficacy and safety of
sugammadex for reversal
of profound rocuronium-induced neurom...
Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
KENILWORTH, N.J., Jan. 17 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP ) announced that Nippon Organon K.K., now part of
Schering-Plough, has filed a New Drug Application with the Japanese
Ministry of Health, Labour and Welfare (MHLW) seeking marketing approval
for its nov...
Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
KENILWORTH, N.J., Jan. 2 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP ) today announced that the U.S. Food and Drug
Administration (FDA) has assigned priority review status to the company's
New Drug Application (NDA) for sugammadex.
Sugammadex is specifically designed to...
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
...the U.S. Food and Drug Administration (FDA); and -- Filing regulatory submissions for important new agents and indications, which now include
sugammadex and asenapine from Organon.
"Schering-Plough now has four full years of accomplishments since we
began this transformation," said Hassan. "In that t...
Schering-Plough Completes Acquisition of Organon BioSciences
...anon), an oral contraceptive; * ORG 50081 (from Organon), for the treatment of insomnia and potentially for hot flashes in menopausal women; *
sugammadex (from Organon), for the reversal of neuromuscular blockade used as part of general anesthesia during surgical procedures; * Tablet-based subling...